All News
Filter News
Found 240 articles
-
Disc Medicine is focused on hepcidin biology to restore red blood cell production in hematologic diseases.
-
Disc Medicine Completes $50 Million Series A Financing led by Novo Holdings A/S to Advance New Therapies Addressing Ineffective Red Blood Cell Production
10/29/2019
Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that restore red blood cell production in hematologic diseases, announced the completion of a $50 million Series A financing.
-
Schrödinger Appoints Drug Discovery Veteran Nancy Thornberry to Board of Directors
9/24/2019
Schrödinger announced the appointment of Nancy Thornberry, a biotech executive recognized for her extensive track record in drug discovery and development, to its Board of Directors.
-
BioSpace Movers & Shakers, Sept. 20
9/20/2019
Biotech and pharma companies from across the globe strengthen their leadership teams and boards of directors with this week's appointments. -
Nimbus Therapeutics Appoints Accomplished Biologist and Research Director Christine Loh, Ph.D., to Lead Biology Team
9/19/2019
Nimbus Therapeutics, a biotechnology company applying deep computational expertise throughout drug discovery and development, today announced that it has appointed Christine Loh, Ph.D., as Senior Vice President, Head of Biology.
-
Schrödinger Announces Expansion of Multi-Target Research Collaboration with Takeda and Achievement of First Significant Preclinical Milestone in Lead Program
9/5/2019
Schrödinger announced the expansion of its multi-year, multi-target drug discovery collaboration with Takeda, as well as Schrödinger’s achievement of the first significant preclinical milestone for the collaboration’s most advanced program.
-
Schrödinger Announces Collaboration with AstraZeneca to Deploy Advanced Computing Technology for Drug Discovery
9/4/2019
Schrödinger announced a collaboration with AstraZeneca to deploy Schrödinger’s advanced computing platform to help accelerate drug discovery efforts.
-
Schrödinger and Qu & Co Announce Collaboration to Advance Quantum Mechanical Computations on Quantum Computers
9/3/2019
Schrödinger and Qu & Co announced a business and scientific collaboration to advance the use of quantum mechanics on complex molecular systems using quantum computing hardware.
-
Schrödinger Expands Drug Discovery Partnership with Morphic Therapeutic
8/13/2019
Extended collaboration leveraging Schrödinger’s computational platform includes new terms with increased and additional milestone payments to Schrödinger
-
Schrödinger Appoints Veteran Pharma Financial Leader Gary Sender to Board of Directors
8/5/2019
Mr. Sender brings over 30 years of financial leadership experience, with a strong track record of success.
-
The M&A moves are expected to increase the oncology pipelines of both companies.
-
Schrödinger Receives Milestone Payment from Ono as Collaborative Program Advances
7/12/2019
Schrödinger announced receipt of a milestone payment from Ono Pharmaceutical Co., Ltd. as part of a collaboration leveraging Schrödinger’s advanced computational platform to develop novel therapeutic candidates acting on the therapeutic target selected by Ono.
-
Schrödinger Receives Milestone Payment from Sanofi Collaboration
7/11/2019
Milestone marks advancement of second drug discovery program under the collaboration
-
Nimbus Therapeutics and Celgene Expand Alliance to Immunotherapy in Oncology
7/9/2019
Collaboration adds additional program focused on HPK1 inhibitors, potential medicines that could restore proper immune system activity in multiple tumor types
-
Schrödinger Bolsters Translational Science Expertise with Leadership Expansion
6/19/2019
New hires to lead ADME/PK and Clinical Pharmacology for rapidly advancing internal pipeline programs
-
Schrödinger to Present at the Jefferies 2019 Global Healthcare Conference
5/30/2019
Schrödinger today announced that Ramy Farid, Ph.D., chief executive officer, will present at the Jefferies 2019 Global Healthcare Conference on Thursday, June 6, 2019 at 11:00 a.m. ET in New York, NY.
-
The financing is expected to be used to advance the company’s computational platform, as well as expand Schrödinger’s therapeutic pipeline.
-
Schrödinger Announces Close of Latest Financing, Raising Total of $110 Million
5/19/2019
New funding to support platform advancements and proprietary pipeline expansion
-
Schrödinger to Present at May Conferences
5/13/2019
Schrödinger announced that the Company will be presenting on its advanced computational platform, which integrates physics-based molecular simulation and machine learning to accelerate drug discovery, at the upcoming conferences in May
-
TetraGenetics Appoints Alison Taunton-Rigby, Ellen Baron and Daniel Grau to its Board of Directors
5/2/2019
Biopharma and Investment Executives with Deep Industry Experience to Support Continued Growth of TetraGenetics Ion Channel Pipeline and Platform